DADI Share Price | Dar Al Dawa Development & Investment Co. Ltd. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Dar Al Dawa Development & Investment Co. Ltd. with Similar Stocks

Hayat Pharmaceutical Industries Co. Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROCE of 8.76%

The company has been able to generate a Return on Capital Employed (avg) of 8.76% signifying low profitability per unit of total capital (equity and debt)

High Debt Company with a Debt to Equity ratio (avg) at times

With a growth in Operating Profit of 329.53%, the company declared Very Positive results in Dec 25

With ROE of 8.63%, it has a fair valuation with a 0.79 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JOD 62 Million (Small Cap)

P/E

9.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.51

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

26 Million

(Quarterly Results - Dec 2025)

Net Profit:

4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

3.45%

6 Months

7.14%

1 Year

0.38%

2 Years

-2.74%

3 Years

17.65%

4 Years

17.65%

5 Years

4.35%

Dar Al Dawa Development & Investment Co. Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.94%

EBIT Growth (5y)

27.83%

EBIT to Interest (avg)

2.02

Debt to EBITDA (avg)

2.90

Net Debt to Equity (avg)

0.66

Sales to Capital Employed (avg)

8.90

Tax Ratio

9.75%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

8.76%

ROE (avg)

9.51%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.79

EV to EBIT

7.93

EV to EBITDA

5.47

EV to Capital Employed

0.88

EV to Sales

0.92

PEG Ratio

0.27

Dividend Yield

ROCE (Latest)

11.06%

ROE (Latest)

8.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 36.36% vs -2.09% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 216.67% vs 0.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.50",
          "val2": "18.70",
          "chgp": "36.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.80",
          "val2": "2.30",
          "chgp": "326.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.80",
          "val2": "1.20",
          "chgp": "216.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "384.50%",
          "val2": "70.90%",
          "chgp": "31.36%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.49% vs 8.41% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 81.08% vs 19.35% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "81.60",
          "val2": "81.20",
          "chgp": "0.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "27.30",
          "val2": "11.40",
          "chgp": "139.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.90",
          "val2": "3.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.70",
          "val2": "3.70",
          "chgp": "81.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "335.00%",
          "val2": "90.70%",
          "chgp": "24.43%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

25.50

18.70

36.36%

Operating Profit (PBDIT) excl Other Income

9.80

2.30

326.09%

Interest

1.00

Exceptional Items

0.00

Consolidate Net Profit

3.80

1.20

216.67%

Operating Profit Margin (Excl OI)

384.50%

70.90%

31.36%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 36.36% vs -2.09% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 216.67% vs 0.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

81.60

81.20

0.49%

Operating Profit (PBDIT) excl Other Income

27.30

11.40

139.47%

Interest

3.90

Exceptional Items

0.00

-0.10

100.00%

Consolidate Net Profit

6.70

3.70

81.08%

Operating Profit Margin (Excl OI)

335.00%

90.70%

24.43%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.49% vs 8.41% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 81.08% vs 19.35% in Dec 2024

All Annual Results

Company CV

About Dar Al Dawa Development & Investment Co. Ltd.

Dar Al Dawa Development & Investment Co. Ltd.

Pharmaceuticals & Biotechnology

Dar Al Dawa Development and Investment Company PSC is a Jordan-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical and consumer health products. The Company’s main activities are producing medical, chemical and pharmaceutical products, and importing pharmaceutical products. The Company operates an integrated network of 11 manufacturing facilities spread across Jordan, Middle East and North Africa region, as well as Romania. Its Pharmaceutical Development Unit focuses on the process developing of various dosage forms including tablets, capsules, liquids, dry suspensions, suppositories, creams, ointments, gels, parenterals, ophthalmic and nasal preparations. The Analytical Research unit engages in the analytical method development, validation, physiochemical characterization and stability studies.

Company Coordinates

Company Details

Dar Al Dawa Dvlpmnt & Instmnt Co Bldg, Wadi Saqrah Street, Al Rabia Area, P.O.Box 9364, AMMAN None : 11191

Tel: 962 6 5727132

http://www.dadgroup.com/

Registrar Details